Visser Nicole C M, Reijnen Casper, Massuger Leon F A G, Nagtegaal Iris D, Bulten Johan, Pijnenborg Johanna M A
Departments of Pathology and Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, the Netherlands.
Obstet Gynecol. 2017 Oct;130(4):803-813. doi: 10.1097/AOG.0000000000002261.
To assess the agreement between preoperative endometrial sampling and final diagnosis for tumor grade and subtype in patients with endometrial carcinoma.
MEDLINE, EMBASE, ClinicalTrials.gov, and the Cochrane library were searched from inception to January 1, 2017, for studies that compared tumor grade and histologic subtype in preoperative endometrial samples and hysterectomy specimens.
In eligible studies, the index test included office endometrial biopsy, hysteroscopic biopsy, or dilatation and curettage; the reference standard was hysterectomy. Outcome measures included tumor grade, histologic subtype, or both.
TABULATION, INTEGRATION, AND RESULTS: Two independent reviewers assessed the eligibility of the studies. Risk of bias was assessed (Quality Assessment of Diagnostic Accuracy Studies). A total of 45 studies (12,459 patients) met the inclusion criteria. The pooled agreement rate on tumor grade was 0.67 (95% CI 0.60-0.75) and Cohen's κ was 0.45 (95% CI 0.34-0.55). Agreement between hysteroscopic biopsy and final diagnosis was higher (0.89, 95% CI 0.80-0.98) than for dilatation and curettage (0.70, 95% CI 0.60-0.79; P=.02); however, it was not significantly higher than for office endometrial biopsy (0.73, 95% CI 0.60-0.86; P=.08). The lowest agreement rate was found for grade 2 carcinomas (0.61, 95% CI 0.53-0.69). Downgrading was found in 25% and upgrading was found in 21% of the endometrial samples. Agreement on histologic subtypes was 0.95 (95% CI 0.94-0.97) and 0.81 (95% CI 0.69-0.92) for preoperative endometrioid and nonendometrioid carcinomas, respectively.
Overall there is only moderate agreement on tumor grade between preoperative endometrial sampling and final diagnosis with the lowest agreement for grade 2 carcinomas.
评估子宫内膜癌患者术前子宫内膜取样与肿瘤分级及亚型最终诊断之间的一致性。
检索MEDLINE、EMBASE、ClinicalTrials.gov和Cochrane图书馆,检索时间从建库至2017年1月1日,查找比较术前子宫内膜样本与子宫切除标本中肿瘤分级和组织学亚型的研究。
在符合条件的研究中,索引检测包括门诊子宫内膜活检、宫腔镜活检或刮宫术;参考标准为子宫切除术。结局指标包括肿瘤分级、组织学亚型或两者。
制表、整合与结果:两名独立评审员评估研究的合格性。评估偏倚风险(诊断准确性研究的质量评估)。共有45项研究(12459例患者)符合纳入标准。肿瘤分级的合并一致性率为0.67(95%CI 0.60 - 0.75),Cohen's κ为0.45(95%CI 0.34 - 0.55)。宫腔镜活检与最终诊断之间的一致性(0.89,95%CI 0.80 - 0.98)高于刮宫术(0.70,95%CI 0.60 - 0.79;P = 0.02);然而,其并不显著高于门诊子宫内膜活检(0.73,95%CI 0.60 - 0.86;P = 0.08)。2级癌的一致性率最低(0.61,95%CI 0.53 - 0.69)。在25%的子宫内膜样本中发现降级,21%的样本中发现升级。术前子宫内膜样癌和非子宫内膜样癌组织学亚型的一致性分别为0.95(95%CI 0.94 - 0.97)和0.81(95%CI 0.69 - 0.92)。
总体而言,术前子宫内膜取样与最终诊断在肿瘤分级上仅有中度一致性,2级癌的一致性最低。